Get started
Author

Hermina Sánta

Observed name: Hermina Santa
ORCID: 0009-0006-4319-0782
Observed ORCID: 0009-0006-4319-0782
OpenAlex ID: A5081916975
Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma
2023 · Ákos Nagy, Bence Bátai, et al. · Journal of Internal Medicine · 12
PDF
Low‐burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation
2023 · Tamás László, Lili Kotmayer, et al. · The Journal of Pathology Clinical Research · 7
PDF
Ixazomib-Lenalidomide-Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: A Hungarian Real-World Analysis
2025 · Hermina Sánta, Laura Regáli, et al. · Journal of Clinical Medicine · 1
PDF
Listeriosis myeloma multiplexben
2023 · Hermina Sánta, Zsófia Müller, et al. · Hematológia–Transzfuziológia · 1
Pharmacological strategies for relapsed multiple myeloma after T-cell engager therapy: From molecular mechanisms to translational opportunities
2026 · Hermina Sánta, Gergely Varga, et al. · Advances in Translational Research
P1245: Parallel Testing of Liquid Biopsy (ctdna) and Tissue Biopsy Samples Reveals a Higher Frequency of Targetable Ezh2 Mutations in Follicular Lymphoma
2023 · Bence Bátai, Ákos Nagy, et al. · HemaSphere
Pb1909: Low-burden Tp53 Mutations Represent Frequent Genetic Events in Cll With an Increased Risk for Treatment Initiation
2023 · Tamás László, Lili Kotmayer, et al. · HemaSphere
Works count: 7
Citation count: 21
H-index: 2
I10-index: 1
Year
Topic
Type